Drug Trial Radar · NCT06173570
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
428
Actual
Start
Jan 19, 2024
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.
Conditions
- Dyslipidemia
Interventions
AZD0780Drug
AZD0780 administered orally, once daily for 12 weeks
PlaceboDrug
Placebo administered orally, once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12Time frame: From first day of treatment up to week 12
Locations
55 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Lincoln, California
Research Site
Palm Springs, California
Research Site
Santa Ana, California
Research Site
Boca Raton, Florida
Research Site
Hialeah, Florida
Research Site
Inverness, Florida
Research Site
Jacksonville, Florida
Research Site
Indianapolis, Indiana
Research Site
Louisville, Kentucky
Research Site
New Windsor, New York
Research Site
Greensboro, North Carolina
Research Site
Fargo, North Dakota
Research Site
San Marcos, Texas
Research Site
Barrie, Ontario, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Cambridge, Ontario, Canada
Research Site
Concord, Ontario, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Benešov, Czechia
Research Site
Brandýs nad Labem, Czechia
Research Site
Brno, Czechia
Research Site
Louny, Czechia
Research Site
Náchod, Czechia
Research Site
Prague, Czechia
Research Site
Příbram, Czechia
Research Site
Teplice, Czechia
Research Site
Uherské Hradiště, Czechia
Research Site
Aarhus, Denmark
Research Site
Herning, Denmark
Research Site
Hvidovre, Denmark
Research Site
Svendborg, Denmark
Research Site
Viborg, Denmark
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Orosháza, Hungary
Research Site
Pécs, Hungary
Research Site
Chūōku, Japan
Research Site
tabashi City, Japan
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.